We're building a better ClinicalTrials.gov. Check it out and tell us what you think!

Key Record Dates

ClinicalTrials.gov Identifier: NCT04762641
Brief Title: This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects With Any Progressive Locally Advanced or Metastatic Solid Tumors

First Submitted : January 28, 2021
First Submitted that Met QC Criteria : February 17, 2021
First Posted : February 21, 2021

Last Update Submitted that Met QC Criteria : October 5, 2021
Last Update Posted : October 6, 2021